CNSP - CNS Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CNSP

CNS PHARMACEUTICALS, INC.

NASDAQ

$5.52

▲ UP 0.10% (0.01)

KEY STATISTICS

Market Cap$8.07 M

52w High$10.59

52w Low$1.90

Dividend Yield—

Frequency—

P/E-0.22

Volume3.70K

Shares Out.1.46M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Rami Levin

COMPENSATION 2026

Salary$580,000

Stock Awards$0

Incentive Plan Pay$319,000

All Other Comp.$0

Total$1,168,591

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 8, 2019

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$0.50

Target Low$0.50

Target Median$0.50

Target Consensus$0.50

UPCOMING EARNINGS

DateNov 18, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-07-22	Reverse	1:12
2025-02-21	Reverse	1:50
2024-06-05	Reverse	1:50
2022-11-29	Reverse	1:30

PRICE

$5.52 ▲ UP 0.10% (+$0.01)

OVERLAYS

About CNS Pharmaceuticals, Inc.

https://www.cnspharma.com ↗

CNS Pharmaceuticals, Inc. develops anti-cancer drugs like Berubicin for brain tumors, with clinical trials and collaborations, based in Houston since 2017.

INDUSTRY

Biotechnology

A PRODUCT CNS PHARMACEUTICALS, INC. IS KNOWN FOR

TPI 287

TPI 287 is a clinical-stage anti-cancer drug targeting aggressive brain tumors like glioblastoma, crossing the blood-brain barrier, and advancing to Phase 2 as CNS Pharmaceuticals' lead development program.